Amendment: SEC Form SC 13G/A filed by Evolus Inc.

$EOLS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $EOLS alert in real time by email
SC 13G/A 1 eols1015242sc13ga2.htm AMENDMENT NO. 2

 

 

Securities and Exchange Commission

Washington, DC 20549

 

SCHEDULE 13G/A

 

 

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

 

Evolus, Inc.

(Name of Issuer)

 

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

 

 

 

30052C107

(CUSIP Number)

 

 

 

September 30, 2024

(Date of Event Which Requires Filing of This Statement)

 

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

¨Rule 13d-1(b)

 

xRule 13d-1(c)

 

¨Rule 13d-1(d)

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 Page 1 of 10 Pages 
  

 

CUSIP No.  30052C107

 

13G/A Page 2 of 10 Pages
1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

Tang Capital Management, LLC

 

2 Check the Appropriate Box if a Member of a Group* (a)
(
b)

3

SEC Use Only

4

Citizenship or Place of Organization

 

DELAWARE

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

0 

6

Shared Voting Power

 

4,847,399

7

Sole Dispositive Power

 

0 

8

Shared Dispositive Power

 

4,847,399

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

4,847,399

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

7.7%  

12

type of reporting person

 

OO

 

 Page 2 of 10 Pages 
  

 

CUSIP No. 30052C107

 

13G/A Page 3 of 10 Pages
1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

KEVIN TANG

 

2 Check the Appropriate Box if a Member of a Group* (a)
(
b)

3 SEC Use Only
4

Citizenship or Place of Organization

 

united states

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

0 

6

Shared Voting Power

 

4,847,399

7

Sole Dispositive Power

 

8

Shared Dispositive Power

 

4,847,399  

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

4,847,399

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

7.7%  

12

type of reporting person

 

IN 

 

 Page 3 of 10 Pages 
  

 

CUSIP No. 30052C107

 

13G/A Page 4 of 10 Pages

1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

TANG CAPITAL PARTNERS, LP

 

2 Check the Appropriate Box if a Member of a Group* (a)
(
b)
3

SEC Use Only

4

Citizenship or Place of Organization

 

DELAWARE

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

6

Shared Voting Power

 

4,447,399

7

Sole Dispositive Power

 

8

Shared Dispositive Power

 

4,447,399

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

4,447,399

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

7.1%  

12

type of reporting person

 

pN 

 

 Page 4 of 10 Pages 
  

 

CUSIP No. 30052C107

 

13G/A Page 5 of 10 Pages
1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

TANG CAPITAL PARTNERS III, INC

 

2 Check the Appropriate Box if a Member of a Group* ( a)
(
b)

3 SEC Use Only
4

Citizenship or Place of Organization

 

NEVADA

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

0 

6

Shared Voting Power

 

400,000

7

Sole Dispositive Power

 

8

Shared Dispositive Power

 

400,000 

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

400,000

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

0.6% 

12

type of reporting person

 

CO 

 

 Page 5 of 10 Pages 
  

 

CUSIP No. 30052C107

 

13G/A Page 6 of 10 Pages
1

NameS of Reporting Persons
I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

 

TANG CAPITAL PARTNERS IV, INC

 

2 Check the Appropriate Box if a Member of a Group* ( a)
(
b)

3 SEC Use Only
4

Citizenship or Place of Organization

 

NEVADA

 

Number of
Shares
BENEFICIALLY
Owned by
Each Reporting
Person with
5

Sole Voting Power

 

0 

6

Shared Voting Power

 

0

7

Sole Dispositive Power

 

8

Shared Dispositive Power

 

0

9

Aggregate Amount Beneficially Owned by each Reporting Person

 

0

10

Check Box if the Aggregate Amount in Row (9) excludes certain shares

 

¨

11

Percent of Class represented by amount in row 9

 

0% 

12

type of reporting person

 

CO 

 

 Page 6 of 10 Pages 
  

 

Item 1(a).Name of Issuer:

 

Evolus, Inc., a Delaware corporation (the "Issuer")

 

Item 1(b).Address of Issuer’s Principal Executive Offices:

 

520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660

 

Item 2(a).Name of Person Filing:

 

This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management and the Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Partners III, Inc. (“Tang Capital Partners III”); and Tang Capital Partners IV, Inc. (“Tang Capital Partners IV”).

 

Item 2(b).Address of Principal Business Office or, if none, Residence:

 

The address of Tang Capital Management, Kevin Tang and Tang Capital Partners is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of Tang Capital Partners III and Tang Capital Partners IV is 5955 Edmond Street, Las Vegas, NV 89118.

 

Item 2(c).Citizenship:

 

Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Tang Capital Partners III and Tang Capital Partners IV are Nevada corporations which are indirectly wholly owned by Tang Capital Partners.

 

Item 2(d).Title of Class of Securities:

 

Common Stock, par value $0.00001 per share (the “Common Stock”)

 

Item 2(e).CUSIP Number: 30052C107

 

Item 3.Not applicable.

 

Item 4.Ownership.

 

(a)Amount Beneficially Owned:

 

Tang Capital Management. Tang Capital Management beneficially owns 4,847,399 shares of the Issuer’s Common Stock.

 

Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners, Tang Capital Partners III and Kevin Tang.

 

Kevin Tang. Kevin Tang beneficially owns 4,847,399 shares of the Issuer’s Common Stock.

 

Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners, Tang Capital Partners III and Tang Capital Management.

 

 Page 7 of 10 Pages 
  

 

Tang Capital Partners. Tang Capital Partners beneficially owns 4,447,399 shares of the Issuer’s Common Stock.

 

Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

 

Tang Capital Partners III. Tang Capital Partners III beneficially owns 400,000 shares of the Issuer’s Common Stock.

 

Tang Capital Partners III shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

 

The percentages used herein are based on 63,094,482 shares of Common Stock outstanding as of July 26, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on July 31, 2024.

 

(b)      Percent of Class:

 

Tang Capital Management 7.7%
Kevin Tang 7.7%
Tang Capital Partners 7.1%
Tang Capital Partners III 0.6%
Tang Capital Partners IV 0.0%

 

(c)       Number of shares as to which such person has:

 

(i)      sole power to vote or to direct the vote:

 

Tang Capital Management 0 shares
Kevin Tang 0 shares
Tang Capital Partners 0 shares
Tang Capital Partners III 0 shares
Tang Capital Partners IV 0 shares

 

(ii)     shared power to vote or to direct the vote:

 

Tang Capital Management 4,847,399 shares
Kevin Tang 4,847,399 shares
Tang Capital Partners 4,447,399 shares
Tang Capital Partners III 400,000 shares
Tang Capital Partners IV 0 shares

 

(iii)    sole power to dispose or to direct the disposition of:

 

Tang Capital Management 0 shares
Kevin Tang 0 shares
Tang Capital Partners 0 shares
Tang Capital Partners III 0 shares
Tang Capital Partners IV 0 shares

 

(iv)    shared power to dispose or to direct the disposition of:

 

Tang Capital Management 4,847,399 shares
Kevin Tang 4,847,399 shares
Tang Capital Partners 4,447,399 shares
Tang Capital Partners III 400,000 shares
Tang Capital Partners IV 0 shares

 

 Page 8 of 10 Pages 
  

 

Item 5.Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

Not applicable.

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 Page 9 of 10 Pages 
  

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Date: November 14, 2024  

 

 

TANG CAPITAL PARTNERS, LP

 

By: Tang Capital Management, LLC, its General Partner

 

 

By: /s/ Kevin Tang  
  Kevin Tang, Manager  

 

TANG CAPITAL PARTNERS III, INC

 

 

By: /s/ Kevin Tang  
  Kevin Tang, Chief Executive Officer  

 

TANG CAPITAL PARTNERS IV, INC

 

 

By: /s/ Kevin Tang  
  Kevin Tang, Chief Executive Officer  

 

 

TANG CAPITAL MANAGEMENT, LLC

 

 

By: /s/ Kevin Tang  
  Kevin Tang, Manager  

 

 

/s/ Kevin Tang  
Kevin Tang  

 

 

Page 10 of 10 Pages

 

 

Get the next $EOLS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EOLS

DatePrice TargetRatingAnalyst
1/29/2024$10.00 → $16.00Equal Weight → Overweight
Barclays
6/23/2022$18.00Buy
Needham
5/12/2022$8.00 → $10.00Underweight → Equal Weight
Barclays
1/20/2022$11.00Hold → Buy
Truist
11/3/2021$22.00 → $15.00Buy
HC Wainwright & Co.
More analyst ratings

$EOLS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45 PM ET - Track 1. The fireside chats can be accessed on the Investor Relations page of the Evolus website here. A replay of the webcast will be available for 90 days after the date of each presentation. About Evolus, Inc. Evolus (NASDAQ:EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation

    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company's common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company's board of directors under the Evolus' 2023 Inducement Incentive Plan, with a grant and vesting commencement date of March 7, 2025, as an inducement material to the new employees entering into employment with Evolus in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest 25% on each annual anniversary of the vesting commencement date. The

    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

    Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full-Year 2024, Representing 30% and 32% Growth Over the Prior Year, Respectively; Results Unchanged from January Preliminary Results GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability1 with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability1 One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense

    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EOLS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$EOLS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$EOLS
SEC Filings

See more

$EOLS
Leadership Updates

Live Leadership Updates

See more
  • Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations
  • Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

    Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:

    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EOLS
Financials

Live finance-specific insights

See more
  • Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

    Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full-Year 2024, Representing 30% and 32% Growth Over the Prior Year, Respectively; Results Unchanged from January Preliminary Results GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability1 with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability1 One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense

    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (877) 407-6184 (U.S.) or (201) 389-0877 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a tel

    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Evolus Reports Third Quarter 2024 Results

    Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% Received Approval for Estyme® Injectable Hyaluronic Acid (HA) Gels in the European Union; Experience Program to Launch Immediately with Full Launch Expected in the Second Half of 2025 Premarket Approval (PMA) Application for Evolysse™ Form and Evolysse™ Smooth Injectable HA Gels Currently Under Review by the U.S. Food and Drug Administration (FDA) with Approval and Launch Expected by September 2025 Narrows Full-Year 2024 Net Revenue Guidance to $260 Million to $266 Million, Representing Year-Over-Year Growth of 29% to 32% Reaffirms Non-GAAP Profitability1 in Q4 2024 and Full Year 2025

    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$EOLS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more